TERT-locus single nucleotide polymorphisms (SNPs) and leucocyte telomere measures are reportedly associated with risks of multiple cancers. Using the iCOGs chip, we analysed ~480 TERT-locus SNPs in breast (n=103,991), ovarian (n=39,774) and BRCA1 mutation carrier (11,705) cancer cases and controls. 53,724 participants have leucocyte telomere measures. Most associations cluster into three independent peaks. Peak 1 SNP rs2736108 minor allele associates with longer telomeres (P=5.8×10 −7 ), reduced estrogen receptor negative (ER-negative) (P=1.0×10 −8 ) and BRCA1 mutation carrier (P=1.1×10 −5 ) breast cancer risks, and altered promoter-assay signal. Peak 2 SNP rs7705526 minor allele associates with longer telomeres (P=2.3×10 −14 ), increased low malignant potential ovarian cancer risk (P=1.3×10 −15 ) and increased promoter activity. Peak 3 SNPs rs10069690 and rs2242652 minor alleles increase ER-negative (P=1.2×10 −12 ) and BRCA1 mutation carrier (P=1.6×10 −14 ) breast and invasive ovarian (P=1.3×10 −11 ) cancer risks, but not via altered telomere length. The cancer-risk alleles of rs2242652 and rs10069690 respectively increase silencing and generate a truncated TERT splicevariant.
Analysis of 4,405 variants in 89,050 European subjects from 41 case-control studies identified three independent association signals for estrogen-receptor-positive tumors at 11q13. The strongest signal maps to a transcriptional enhancer element in which the G allele of the best candidate causative variant rs554219 increases risk of breast cancer, reduces both binding of ELK4 transcription factor and luciferase activity in reporter assays, and may be associated with low cyclin D1 protein levels in tumors. Another candidate variant, rs78540526, lies in the same enhancer element. Risk association signal 2, rs75915166, creates a GATA3 binding site within a silencer element. Chromatin conformation studies demonstrate that these enhancer and silencer elements interact with each other and with their likely target gene, CCND1.
We analyzed 3,872 common genetic variants across the
ESR1 locus (encoding estrogen receptor α) in
118,816 subjects from three international consortia. We found evidence for at
least five independent causal variants, each associated with different phenotype
sets, including estrogen receptor (ER+ or
ER−) and human ERBB2 (HER2+ or
HER2−) tumor subtypes, mammographic density and tumor
grade. The best candidate causal variants for ER− tumors lie
in four separate enhancer elements, and their risk alleles reduce expression of
ESR1, RMND1 and CCDC170,
whereas the risk alleles of the strongest candidates for the remaining
independent causal variant disrupt a silencer element and putatively increase
ESR1 and RMND1 expression.
GWAS have identified a breast cancer susceptibility locus on 2q35. Here we report the
fine mapping of this locus using data from 101,943 subjects from 50 case-control
studies. We genotype 276 SNPs using the ‘iCOGS’ genotyping
array and impute genotypes for a further 1,284 using 1000 Genomes Project data. All
but two, strongly correlated SNPs (rs4442975 G/T and rs6721996 G/A) are excluded as
candidate causal variants at odds against >100:1. The best functional
candidate, rs4442975, is associated with oestrogen
receptor positive (ER+) disease with an odds ratio (OR) in Europeans of 0.85 (95%
confidence interval=0.84−0.87; P=1.7 ×
10−43) per t-allele. This SNP flanks a
transcriptional enhancer that physically interacts with the promoter of
IGFBP5 (encoding insulin-like growth factor-binding protein 5)
and displays allele-specific gene expression, FOXA1 binding and chromatin looping. Evidence suggests that the
g-allele confers increased breast cancer susceptibility through relative
downregulation of IGFBP5, a
gene with known roles in breast cell biology.
Breast cancer risk is strongly associated with an intergenic region on 11q13. We have previously shown that the strongest risk-associated SNPs fall within a distal enhancer that regulates CCND1. Here, we report that, in addition to regulating CCND1, this enhancer regulates two estrogen-regulated long noncoding RNAs, CUPID1 and CUPID2. We provide evidence that the risk-associated SNPs are associated with reduced chromatin looping between the enhancer and the CUPID1 and CUPID2 bidirectional promoter. We further show that CUPID1 and CUPID2 are predominantly expressed in hormone-receptor-positive breast tumors and play a role in modulating pathway choice for the repair of double-strand breaks. These data reveal a mechanism for the involvement of this region in breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.